Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 2/2015

01-04-2015 | Kidney and Bone (SM Moe and IB Salusky, Section Editors)

Defective Skeletal Mineralization in Pediatric CKD

Author: Katherine Wesseling-Perry

Published in: Current Osteoporosis Reports | Issue 2/2015

Login to get access

Abstract

Although traditional diagnosis and treatment of renal osteodystrophy focused on changes in bone turnover, current data demonstrate that abnormalities in skeletal mineralization are also prevalent in pediatric chronic kidney disease (CKD) and likely contribute to skeletal morbidities that continue to plague this population. It is now clear that alterations in osteocyte biology, manifested by changes in osteocytic protein expression, occur in early CKD before abnormalities in traditional measures of mineral metabolism are apparent and may contribute to defective skeletal mineralization. Current treatment paradigms advocate the use of 1,25(OH)2vitamin D for the control of secondary hyperparathyroidism; however, these agents fail to correct defective skeletal mineralization and may exacerbate already altered osteocyte biology. Further studies are critically needed to identify the initial trigger for abnormalities of skeletal mineralization as well as the potential effects that current therapeutic options may have on osteocyte biology and bone mineralization.
Literature
1.
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; S1–130.
2.
Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7:146–52. This is the only pediatric study to evaluate the prevalence of renal osteodystrophy across the spectrum of pre-dialysis CKD.CrossRefPubMedCentralPubMed
3.
Groothoff JW, Offringa M, Van Eck-Smit BL, Gruppen MP, Van De Kar NJ, Wolff ED, et al. Severe bone disease and low bone mineral density after juvenile renal failure. Kidney Int. 2003;63:266–75.CrossRefPubMed
4.
Munns CF, Rauch F, Travers R, Glorieux FH. Three children with lower limb fractures and a mineralization defect: a novel bone fragility disorder? Bone. 2004;35:1023–8.CrossRefPubMed
5.
consortium, A. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345–8.CrossRef
6.•
Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011;79:112–9. This study revealed that, although PTH and bone turnover decrease during therapy with active vitamin D sterols and phosphate binders, defects in mineralization persist.CrossRefPubMed
7.••
Sabbagh Y, Graciolli FG, O’Brien S, Tang W, dos Reis L, Ryan S, et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012;27:1757–72. In conjunction with the 2009 study by Pereira et al, this is one of only 2 studies documenting changes in osteocyte biology that occur early in the course of CKD.CrossRefPubMed
8.••
Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009;45:1161–8. This was the first study to describe that osteocyte biology is altered in pediatric CKD and to describe that bone FGF23 expression correlates with parameters of skeletal mineralization in the pediatric CKD population.CrossRefPubMedCentralPubMed
9.
Jensen PR, Andersen TL, Soe K, Hauge EM, Bollerslev J, Amling M, et al. Premature loss of bone remodeling compartment canopies is associated with deficient bone formation: a study of healthy individuals and patients with Cushing’s syndrome. J Bone Miner Res. 2012;27:770–80.CrossRefPubMed
10.
Kupisiewicz K, Boissy P, Abdallah BM, Hansen FD, Erben RG, Savouret JF, et al. Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts. Calcif Tissue Int. 2010;87:437–49.CrossRefPubMedCentralPubMed
11.
O’Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoSONE. 2008;3:e2942.CrossRefPubMedCentralPubMed
12.
Manolagas SC. Cellular and molecular mechanisms of osteoporosis. Aging (Milano). 1998;10:182–90.
13.
Karsenty G. Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet. 2008;9:183–96.CrossRefPubMed
14.
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.CrossRefPubMed
15.
Nijweide PJ, Burger EH, Feyen JH. Cells of bone: proliferation, differentiation, and hormonal regulation. Physiol Rev. 1986;66:855–86.PubMed
16.
Shalhoub V, Faust J, Boyle WJ, Dunstan CR, Kelley M, Kaufman S, et al. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J Cell Biochem. 1999;72:251–61.CrossRefPubMed
17.
Paiva KB, Granjeiro JM. Bone tissue remodeling and development: Focus on matrix metalloproteinase functions. Arch Biochem Biophys. 2014;561C:74–87.CrossRef
18.
Frost HM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res. 1969;3:211–37.CrossRefPubMed
19.
20.
Neuman WFN, Margaret W. (1958). The chemical dynamics of bone mineral, The University of Chicago Press.
21.
Schartum S, Nichols Jr G. Concerning pH gradients between the extracellular compartment and fluids bathing the bone mineral surface and their relation to calcium ion distribution. J Clin Invest. 1962;41:1163–8.CrossRefPubMedCentralPubMed
22.
Green J, Yamaguchi DT, Kleeman CR, Muallem S. Cytosolic pH regulation in osteoblasts. Interaction of Na + and H+ with the extracellular and intracellular faces of the Na+/H+ exchanger. J Gen Physiol. 1988;92:239–61.CrossRefPubMed
23.
Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science. 1989;245:855–7.CrossRefPubMed
24.
Bergwitz C, Roslin NM, Tieder M, Loredo-Osti JC, Bastepe M, Abu-Zahra H, et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet. 2006;78:179–92.CrossRefPubMedCentralPubMed
25.
Lorenz-Depiereux B, Bastepe M, et-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. NatGenet. 2006;38:1248–50.CrossRefPubMed
26.
Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in end-stage renal failure—an evolving disorder. Kidney Int. 1993;43:436–42.CrossRefPubMed
27.
Salusky IB, Foley J, Nelson P, Goodman WG. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med. 1991;324:527–31.CrossRefPubMed
28.
Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7:146–52.CrossRefPubMedCentralPubMed
29.
Salusky IB, Kuizon BD, Belin TR, Ramirez JA, Gales B, Segre GV, et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int. 1998;54:907–14.CrossRefPubMed
30.
Waller S, Shroff R, Freemont AJ, Rees L. Bone histomorphometry in children prior to commencing renal replacement therapy. Pediatr Nephrol. 2008;23:1523–9.CrossRefPubMed
31.•
Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, et al. Value of the new bone classification system in pediatric renal osteodystrophy. ClinJAmSocNephrol. 2010;5:1860–6. This is the only study on the ability of different biochemical parameters to predict bone mineralization, as well as turnover, in the pediatric dialysis population.CrossRefPubMedCentralPubMed
32.•
Sanchez CP, Salusky IB, Kuizon BD, Ramirez JA, Gales B, Ettenger RB, et al. Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int. 1998;53:1358–64. This manuscript was the first description of bone histology post kidney transplantation.CrossRefPubMed
33.•
Tamminen IS, Valta H, Jalanko H, Salminen S, Mayranpaa MK, Isaksson H, et al. Pediatric solid organ transplantation and osteoporosis: a descriptive study on bone histomorphometric findings. Pediatr Nephrol. 2014;29:1431–40. This manuscript presents the most current data on bone histomorphometric parameters of pediatric transplant recipients.CrossRefPubMed
34.
National Kidney F. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis. 2005;46:S1–121.CrossRef
35.
Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011;79:112–9.CrossRefPubMed
36.
Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest. 2012;122:1803–15.CrossRefPubMedCentralPubMed
37.
De Schutter TM, Behets GJ, Jung S, Neven E, D’Haese PC, Querfeld U. Restoration of bone mineralization by cinacalcet is associated with a significant reduction in calcitriol-induced vascular calcification in uremic rats. Calcif Tissue Int. 2012;91:307–15.CrossRefPubMed
38.
North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2008 Annual Report. 2008.
39.
North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2006 Annual Report. 2006.
40.
North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report. 2005.
41.•
Bacchetta J, Wesseling-Perry K, Kuizon B, Pereira RC, Gales B, Wang HJ, et al. The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial. Clin J Am Soc Nephrol. 2013;8:824–32. This study is the only one to evaluate bone histomorphometry in pediatric dialysis patients receiving growth hormone.CrossRefPubMedCentralPubMed
42.
Sanchez CP, Salusky IB, Kuizon BD, Abdella P, Juppner H, Goodman WG. Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Kidney Int. 1998;54:1879–87.CrossRefPubMed
43.••
Nawrot-Wawrzyniak K, Misof BM, Roschger P, Panczyk-Tomaszewska M, Ziolkowska H, Klaushofer K, et al. Changes in bone matrix mineralization after growth hormone treatment in children and adolescents with chronic kidney failure treated by dialysis: a paired biopsy study. Am J Kidney Dis. 2013;61:767–77. This manuscript demonstrated that bone matrix mineralization characteristics change in pediatric transplant recipients treated with growth hormone.CrossRefPubMed
44.
Portale AA, Wolf M, Juppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, and Salusky IB. Disordered FGF23 and Mineral Metabolism in Children with CKD. Clin J Am Soc Nephrol. 2013.
45.
Gomes SA, dos Reis LM, de Oliveira I, Noronha IL, Jorgetti V, Heilberg IP. Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate [corrected]: an improved method for immunohistochemistry. J Bone Miner Metab. 2008;26:110–3.CrossRefPubMed
46.
Pereira RC, Jüppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009;45:1161–8.CrossRefPubMedCentralPubMed
47.
Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–8.CrossRefPubMed
48.
Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, and Wolf M. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011.
49.
50.
Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008;23:939–48.CrossRefPubMed
51.•
Pereira RC, D A, Khouzam N, Bowen R, Freymiller E, Salusky IB, Wesseling-Perry K. Primary osteoblast-like cells from patients with end stage kidney disease reflext gene expression, proliferation and mineralization characteristics ex vivo. Kidney Int. 2014. This manuscript demonstrated that osteoblasts from patients with CKD are phenotypically different than their counterparts from individuals with normal kidney function, suggesting that future studies on the pathophysiology of bone disease will require an understanding of intrinsic alterations to bone cells that occur in the context of CKD.
52.•
Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, et al. Relationship between plasma FGF-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. JClinEndocrinolMetab. 2009;94:511–7. This manuscript was the first to identify that FGF23 is a marker of how well bone is mineralized in patients treated with maintenance dialysis.CrossRefPubMedCentralPubMed
53.
Lima F, El-Husseini A, Monier-Faugere MC, David V, Mawad H, Quarles D, and Malluche HH. FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis. Clin Nephrol. 2014.
54.
Oliveira RB, Cancela AL, Graciolli FG, dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5:286–91.CrossRefPubMedCentralPubMed
55.
Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, and Ortiz A. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant. 2011.
56.
Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2012;27:784–90.CrossRefPubMed
Metadata
Title
Defective Skeletal Mineralization in Pediatric CKD
Author
Katherine Wesseling-Perry
Publication date
01-04-2015
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 2/2015
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-015-0253-4

Other articles of this Issue 2/2015

Current Osteoporosis Reports 2/2015 Go to the issue

Nutrition, Exercise, and Lifestyle in Osteoporosis (CM Weaver and R Daly, Section Editors)

Diet, Gut Microbiome, and Bone Health

Rare Bone Disease (CB Langman and E Shore, Section Editors)

Hypophosphatemic Rickets: Lessons from Disrupted FGF23 Control of Phosphorus Homeostasis

Skeletal Development (E Schanipani and E Zelzer, Section Editors)

The Immunological Contribution to Heterotopic Ossification Disorders

Rare Bone Disease (CB Langman and E Shore, Section Editors)

Hyperphosphatemic Familial Tumoral Calcinosis: Genetic Models of Deficient FGF23 Action

Osteoporosis and Cancer (P Clezardin and G van der Pluijm, Section Editors)

Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss

Osteocytes (T Bellido and J Klein-Nulend, Section Editors)

Osteocyte Shape and Mechanical Loading